RecruitingPhase 4NCT06848946

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Studying NON RARE IN EUROPE: Primary adult open-angle glaucoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Glaukos Corporation
Principal Investigator
Study Director
Glaukos Corporation
Intervention
iDose TR (travoprost intracameral implant) 75 µg in conjunction with cataract surgery(combination_product)
Enrollment
132 target
Eligibility
45 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06848946 on ClinicalTrials.gov

Other trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

Additional recruiting or active studies for the same condition.

See all trials for NON RARE IN EUROPE: Primary adult open-angle glaucoma

← Back to all trials